Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Pivotal Clinical Validation Data for Afirma Genomic Sequencing Classifier Presented at World Congress on Thyroid Cancer
Enhanced Classifier Identifies 30% More Benign Patients Than Original, Flagship Test SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced today that an oral presentation of data from the pivotal clinical validation study of the Afirma Genomic Sequencing Classifier
View HTML
Toggle Summary Veracyte Announces Positive Data From Three Afirma Studies to Be Presented at World Congress on Thyroid Cancer
-- Oral Presentation Highlights Next-Generation Afirma Genomic Sequencing Classifier -- SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) today announced that an oral presentation of data from the pivotal clinical validation study of the company's next-generation Afirma
View HTML
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Monday, July 31, 2017
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)-- Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its second quarter 2017 financial results after the close of market on Monday, July 31, 2017 . Following the announcement, Veracyte's management will host a live conference call and
View HTML
Toggle Summary Veracyte Announces Publication of Study Supporting the Development of Envisia™ Genomic Classifier for IPF in Annals of the American Thoracic Society
SOUTH SAN FRANCISCO, Calif. , June 27, 2017 /PRNewswire/ --  Veracyte, Inc. (NASDAQ: VCYT) announced today that results of a study supporting the early development of the Envisia Genomic Classifier have been published online in the Annals of the American Thoracic Society .  The genomic test,
View HTML
Toggle Summary Veracyte Named a San Francisco Bay Area "Top Workplace" For Fourth Consecutive Year
SOUTH SAN FRANCISCO, Calif. , June 26, 2017 /PRNewswire/ --  Veracyte, Inc. (NASDAQ: VCYT) announced today that it has been awarded a 2017 Top Workplaces honor by the Bay Area News Group . This marks the fourth consecutive year that Veracyte has received this prestigious award, which is based
View HTML
Toggle Summary Veracyte to Present at William Blair 2017 Growth Stock Conference
SOUTH SAN FRANCISCO, Calif. , June 1, 2017 /PRNewswire/ --  Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the William Blair 2017 Growth Stock Conference on Thursday, June 15, 2017 at 8:00 a.m. CT in Chicago, IL.
View HTML
Toggle Summary Veracyte Announces Clinical Validation Data Demonstrating Envisia™ Genomic Classifier's Performance in Improving Idiopathic Pulmonary Fibrosis Diagnosis Presented at ATS 2017
SOUTH SAN FRANCISCO, Calif. , May 23, 2017 /PRNewswire/ --  Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced today that pivotal clinical validation data demonstrating the
View HTML
Toggle Summary Veracyte Announces Anthem Coverage for the Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis
-- Every Major Health Plan in the U.S. Now Covers the Company's Genomic Test --
View HTML
Toggle Summary Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology"
-- Findings suggest that test's use reduces invasive lung-cancer diagnostic procedures by 28 percent and is cost-effective --
View HTML
Toggle Summary Veracyte Announces Six Studies Highlighting Value of Company's Genomic Classifiers in Lung Cancer and Idiopathic Pulmonary Fibrosis To Be Presented at ATS 2017
- New data reinforce role of Percepta® Bronchial Genomic Classifier and Envisia™ Genomic Classifier in diagnosis of difficult-to-distinguish pulmonary diseases -
View HTML